Tibolone and the promise of ideal hormone-replacement therapy.
نویسنده
چکیده
n engl j med 359;7 www.nejm.org august 14, 2008 753 Future PCI/stent use among stable angina patients could 2. depend on COURAGE: managed care first report. (Accessed July 25, 2008, at http://www.mccfirstreport.com/show_story. php?newsid=1172.) Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on 3. quality of life in patients with stable coronary disease. N Engl J Med 2008;359:677-87. Spertus JA, Winder JA, Dewhurst TA, et al. Development and 4. evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol 1995;25:333-41. Hays RD, Morales LS. The RAND-36 measure of health5. related quality of life. Ann Med 2001;33:350-7. Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical ther6. apy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008;117: 1283-91. ACC NCDR data. Durham, NC: Duke Clinical Research Insti7. tute, 2008.
منابع مشابه
Economic impact of tibolone compared with continuous-combined hormone replacement therapy in the management of climacteric symptoms in postmenopausal women
Health technology The study assessed a 3-year treatment course of tibolone, a synthetic steroid that has estrogenic, progestogenic and androgenic properties, in the management of postmenopausal women with climacteric symptoms. Tibolone was taken daily at a dose of 2.5 mg and was taken orally. The treatment was compared with continuous combined hormone replacement therapy, which comprised conjug...
متن کاملPolycythaemia Secondary to Hormone Replacement Therapy with Tibolone
We present the case report of a patient with severe polycythaemia associated with tibolone. In our 65-year-old postmenopausal patient who initially presented with haemoglobin 203 g/L [115-160] and haematocrit 0.63 [0.32-0.47], the cessation of tibolone, a synthetic hormone replacement therapy, led to a dramatic and sustained resolution of this patient's polycythaemia to normal haematological va...
متن کاملPostmenopausal HRT and tibolone in relation to muscle strength and body composition.
OBJECTIVES Sarcopenia, the loss of muscle mass with age, has a great impact on physical function, and especially in postmenopausal women, who experience a greater decline in muscle strength than do men of similar age. Conventional hormone replacement therapy (HRT) may diminish this loss of muscle strength and may even increase muscle strength. However, HRT is not currently promoted for this ind...
متن کاملIn vivo and in vitro estrogenic and progestagenic actions of Tibolone.
Estrogen and progestin combination in hormone replacement therapy (HRT) increases the incidence of breast cancer, but decreases the endometrial cancer risk of unopposed estrogen. Therefore, a SERM such as Tibolone, that delivers the beneficial, but not the adverse side effects, of steroid hormones would be clinically advantageous. However, data from the Million Women Study suggests that Tibolon...
متن کاملMammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy.
OBJECTIVE To compare the effects of tibolone, estriol and conventional hormone replacement therapy (HRT) on mammographic parenchymal density in postmenopausal women. DESIGN AND SETTING This was a non-randomised, prospective, longitudinal, comparative study conducted at two specialist outpatient clinics in Chile. PATIENTS AND PARTICIPANTS 210 non-obese, postmenopausal women aged <65 years wi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The New England journal of medicine
دوره 359 7 شماره
صفحات -
تاریخ انتشار 2008